Description
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 5
Primary Industries
- Drugs
- Diabetes Treatment
- Pharmaceuticals
- Therapeutic
- Cancer
- Antibody
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 305892
Licensor is engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People’s Republic of China.
Licensee entity is a comprehensive pharmaceutical and drug manufacturing company, with an increasing focus on its research and development of new products focusing the therapeutic area of oncology, among others.
IPSCIO Record ID: 2776
IPSCIO Record ID: 27724
IPSCIO Record ID: 289232
Licensee hereby grants to Licensor an exclusive license with sublicensing rights under Licensee Technology, to research, develop, formulate, make, have made, use, sell, offer for sale, import and export Products in the Field of Use in the Licensor Territory.
Licensed Patent Rights shall mean the patents and patent applications listed and any Patent Rights based thereon.
US Patent #5,594,100 – Epitope for prevention of type I diabetes
US Application #09/255,668 – Methods for treating diabetes using peptide analogs
Licensed Technology shall mean any technology, trade secrets, know-how and other intellectual property (other than Trademarks) directed to products, processes, formulations and/or methods and any biological materials owned or Controlled on the Effective Date or to be owned or Controlled thereafter by Licensor or its Affiliates which are necessary to research, develop, formulate, make, use or sell NBI-6024 and shall include the Licensed Patent Rights, Licensor Data and Manufacturing Technology.
Licensor Data shall mean the pre-clinical and clinical data collected by Licensor or its Affiliates in support of the CTX.
CTX shall mean the NBI-6024 CTX filed by Licensor with the Medicines Control Agency in the United Kingdom on December 15, 1998.
NBI-6024 shall mean altered peptide ligand as defined by the amino acid sequence set forth. NBI-6024 is the acetate salt of a synthetic peptide of 15 naturally occurring amino acids based on a sequence derived from the B chain of human insulin. All GLP safety studies and proposed clinical studies will use fully characterized GMP material.
Manufacturing Technology shall mean technology and know-how owned or Controlled by Licensor or its Affiliates which relate to the manufacture of NBI-6024 as set forth in the CTX and any other technology, know-how or standard operating procedures implemented by Licensor or its Affiliates which are actually being used by Licensor or its Affiliates to manufacture Products during the term of this Agreement.
Taisho Technology shall mean any technology, trade secrets, know-how and other intellectual property (other than Trademarks) directed to products, processes, formulations and/or methods and any biological materials owned or Controlled on the Effective Date or to be owned or Controlled thereafter by Taisho or its Affiliates which are necessary to research, develop, formulate, make, useor sell NBI-6024.
Patent Right shall mean patent applications, patents issuing thereon and any extensions or restorations by existing or future extension or restoration mechanisms including Supplementary Protection Certificates or the equivalent thereof, renewals, continuations, continuations-in-part, divisions, patents-of-addition, and/or reissues of any patent, which have not lapsed, been canceled or become abandoned and have not been declared invalid or unenforceable by an unreversed and unappealable decision or judgement of a court or other appropriate body of competent jurisdiction.
IPSCIO Record ID: 302213
Enoblituzumab is a humanized antibody directed at B7-H3, a member of the B7 family of T cell checkpoint regulators. B7-H3 is a promising immuno-oncology drug target as it is widely expressed across multiple tumor types and plays a key role in regulating immune response against cancers. Increasing pre-clinical and clinical evidence suggests that antibodies targeting the two T cell checkpoint molecules—B7-H3 and PD-1—work synergistically in treating cancer. Given B7-H3’s critical role, enoblituzumab has a wide range of cancer applications as either a monotherapy or in combination with PD-1 therapies. At the molecular level, enoblituzumab is engineered to possess an enhanced anti-tumor ADCC function and is at the forefront in global clinical development. Originally developed by Licensor, enoblituzumab has been evaluated in multiple clinical trials as a monotherapy or in combination with CTLA-4 or PD-1 therapies in patients with B7-H3-expressing cancers. Enoblituzumab is also being evaluated in a neoadjuvant Phase 2 study as a single agent in patients with intermediate and high-risk localized prostate cancer.
Licensee and its subsidiaries are principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People’s Republic of China (the “PRCâ€) and other countries and regions.
